Abstract

Timetable

Download Conference Program

Download All Abstracts

Zoom Access

Plenary Lectures Day1　Day2　Day3　Day4

MSSJ Award Lectures Day1

Oral Sessions Day2　Day3　Day4

Poster Presentations Day1　Day2　Day3　Day4

Late-Breaking Posters Day1

Luncheon Seminars Day2　Day3　Day4

Teatime Sessions Day3

Corporate Posters Day2　Day3　Day4

Corporate Program

Oral Sessions

Day 4, June 25（Wed.）　11:55-12:10

Room C (Top of Yaima)

• 4C-O1-1155
• PDF

Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer therapy

(¹NIBN, ²Kyoto Univ., ³NCCH, ⁴Osaka Univ., ⁵NMS)
^oJun Adachi^1,2, Hirokazu Shoji³, Hidekazu Hirano³, Yosui Nojima^1,4, Daigo Gunji^1,2, Akina Shinkura^1,2, Satoshi Muraoka¹, Yuichi Abe¹, Ryohei Narumi¹, Chikako Nagao⁴, Masahiko Aoki³, Kazutaka Obama², Kazufumi Honda⁵, Kenji Mizuguchi^1,4, Takeshi Tomonaga¹, Takaki Yoshikawa³, Ken Kato³, Narikazu Boku³

Gastric cancer subtypes are defined based on TMT-phosphoproteomics of fresh-frozen biopsy samples from 84 naïve gastric cancer patients. Subsequent serial biopsy analysis has unveiled the dynamic transitions within cancer cells, along with the concomitant rewiring of the kinome network, ultimately resulting in the acquisition of the EMT subtype throughout the course of treatment. A strong correlation between EMT and neutrophil level/NETosis status was observed.The clinical potentials of AXL inhibitors in late-stage gastric cancer patients are indicated.

---